Latest Conference Coverage

KP1077 Shows Promise as Potential Treatment for Idiopathic Insomnia in Phase 2 Trial

After 5 weeks of open-label treatment, KP1077-treated patients showed mild adverse events that were typical for a central nervous system stimulant.

Recognizing the Clinical Features of MOGAD for Diagnosis: Eoin P. Flanagan, MB, BCh

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]

Phase 4 PROVIDE Study Aims to Assess Presence and Concentration of Ublituximab in Breastmilk

Study establishes protocols for ublituximab use in breastfeeding patients with MS, enhancing treatment decision-making.

CD40L Inhibitor Frexalimab to be Tested in Phase 3 Trials of Relapsing MS and Non-Relapsing Secondary Progressive MS

The phase 3 trials are expected to assess the therapeutic potential of frexalimab dosed every 4 weeks in both patients with relapsing MS and non-relapsing secondary progressive MS.

Ocrelizumab Effective in Diverse Populations, Cladribine Safe After Switching DMTs, High Rates of Burnout for MS Physicians

Neurology News Network for the week ending June 1, 2024. [WATCH TIME: 4 minutes]

The Challenge of Treating Fatigue in Multiple Sclerosis: Anthony Feinstein, MPhil, PhD, FRCP

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

Understanding the Clinical Advantages of Cladribine and its Impacts on Oligoclonal Bands: Nicola De Stefano, MD, PhD

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]

Safety and Pharmacokinetic Profile of Ocrelizumab in Pediatric MS Mirrors Adult Population

In comparison with adults on ocrelizumab, pediatric patients experienced no clinical relapses and a safety profile that was similar to what was previously observed.

Survey Reveals High Burnout Rates Among Physicians in Multiple Sclerosis Across the United States

A recent survey reported a high prevalence of burnout among physicians treating patients with multiple sclerosis, highlighting long work hours as one of the key factors.

Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Katherine Peters, PhD. [LISTEN TIME: 13 minutes]

Switching to Cladribine Safe and Effective in Older Persons With MS, Real-World Data Show

Within a subgroup of those older than 50 years, most patients who switched to cladribine were relapse free at follow-up, with no new safety signals observed.

Ocrelizumab Maintains Efficacy and Safety in a Diverse Relapsing MS Patient Population at 1-Year

In a new analysis of the CHIMES trial, ocrelizumab displayed a trend toward improved work productivity among minority patients with relapsing multiple sclerosis.

MAGNIFY-MS Analysis Further Demonstrates Cladribine’s Direct Impact on Central Nervous System in MS

Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.

Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

Premedication Regimen of Cetirizine, Dexamethasone, and Famotidine Prior to Ocrelizumab Leads to Less Sedation Issues, Study Shows

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Ofatumumab Positively Impacts Neurofilament Light, NEDA Status Regardless of Race or Ethnic Background

Over a 5-year treatment period, patients on ofatumumab, regardless of race or ethnicity, demonstrated significant reductions in neurofilament light and achieved consistent rates of NEDA-3.

Previewing AHS 2024: Gaining Clinical Insights Into Migraine Care

Howard Rosen, chief executive officer of the American Headache Society, provided commentary on the upcoming annual meeting and the unique types of educational sessions clinicians can look forward to.

Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

Gaining Clinical Insights Into the Benefits of Subcutaneous Ocrelizumab

Scott Newsome, DO, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine, provided clarity on the 1-year data of the OCARINA II study assessing subcutaneous ocrelizumab.

Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology

A trio of clinicians from Cleveland Clinic provided perspectives on the advances in neurology seen at the 2024 AAN Annual Meeting, specifically focusing in on epilepsy, stroke, and multiple sclerosis.

NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas

The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.

Exploring the Association Between Brain Lesions and Takotsubo Syndrome

Frederic Schaper, MD, PhD, an instructor in neurology at Brigham and Women's Hospital, discussed the complex interplay between brain lesions and takotsubo syndrome, a heart condition caused by physical and emotional triggers.

Essentials for Treating Headache as a General Neurologist

Susan W. Broner, MD, the medical director of the Weill Cornell Medicine Headache Program, talked about the essentials of diagnosing and treating various headache disorders from a general neurology perspective.

Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

Sean Pittock, MD, director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.

CMSC 2024: What to Expect From This Year's Annual Meeting

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

NeuroVoices: Jessica Ailani, MD, on Implications of DELIVER Analysis With Eptinezumab for Migraine Prevention

The director of the MedStar Georgetown Headache Center talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.

Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study

Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.

Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]

Closing Thoughts and Outlook of PD Care

Cell-Based Therapies and Bembaneprocel